Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511041 | 1.00 | ADRB2 (0.53) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL14294203 | 0.88 | ADRB2 (0.52) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL4816785 | 0.87 | S1PR1 (0.51) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL4816756 | 0.87 | S1PR1 (0.51) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL7614435 | 0.86 | S1PR1 (0.57) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL4814719 | 0.84 | S1PR1 (0.57) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL4816712 | 0.84 | S1PR1 (0.57) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL4819799 | 0.83 | ADRB2 (0.61) | ADRB2DRD2DRD1DRD4DRD3 | |
| SCHEMBL14539807 | 0.82 | S1PR1 (0.57) | — | |
| SCHEMBL9713370 | 0.81 | ADRB2 (0.59) | ADRB2DRD2DRD1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | PPARG, PPARA, PPARD | ADRB2 41/4885DRD2 1029/4885DRD1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.